938443-20-0

Basic information

• Product Name: 2,4,7-Trichloropyrido[2,3-d]pyrimidine
• Synonyms: 2,4,7-Trichloropyrido[2,3-d]pyrimidine;2,4,7-Trichloropyrido[2,3...;Pyrido[2,3-d]pyriMidine, 2,4,7-trichloro-
• CAS NO: 938443-20-0
• Molecular Formula: C₇H₂Cl₃N₃
• Molecular Weight: 234.473
• Mol File: 938443-20-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 316.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.686 g/cm³
• Refractive Index: 1.688
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.53±0.30(Predicted)
• CAS DataBase Reference: 2,4,7-Trichloropyrido[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,7-Trichloropyrido[2,3-d]pyrimidine(938443-20-0)
• EPA Substance Registry System: 2,4,7-Trichloropyrido[2,3-d]pyrimidine(938443-20-0)

Safety Data

• Hazard Codes: T
• Statements: 25-41
• Safety Statements: 26-39-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 938443-20-0(Hazardous Substances Data)

Usage

Description

2,4,7-Trichloropyrido[2,3-d]pyrimidine is an organic compound that serves as a key intermediate in the synthesis of dual mTORC1/mTORC2 inhibitors. These inhibitors are of significant interest in the field of medicinal chemistry due to their potential as antitumor agents.

Uses

Used in Pharmaceutical Industry:
2,4,7-Trichloropyrido[2,3-d]pyrimidine is used as a synthetic intermediate for the development of dual mTORC1/mTORC2 inhibitors. These inhibitors are designed to target the mechanistic target of rapamycin complex 1 and 2, which play a crucial role in regulating cell growth, proliferation, and survival. By inhibiting these complexes, the dual inhibitors can potentially suppress tumor growth and treat various types of cancer.
In the context of antitumor research, 2,4,7-Trichloropyrido[2,3-d]pyrimidine has been instrumental in the discovery of compounds such as AZD8055 and AZD2014. These compounds have demonstrated promising antitumor activity in preclinical studies, making them potential candidates for further development as therapeutic agents in cancer treatment.

InChI:InChI=1/C7H2Cl3N3/c8-4-2-1-3-5(9)12-7(10)13-6(3)11-4/h1-2H

Upstream product

• 258282-54-1 C₇H₅N₃O₃ 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 938443-19-7 7-chloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 58584-92-2 2-amino-6-chloronicotinic acid 
• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 

Downstream Products

• 938443-21-1 4-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)morpholine 
• 938440-64-3 KU-63794 
• 1009302-61-7 C₂₄H₂₉N₅O₄ 
• 1009302-80-0 C₂₅H₃₂N₆O₃ 
• 1009302-46-8 C₂₄H₃₁N₅O₄ 
• 1009302-47-9 C₂₃H₂₄N₆O₃ 
• 1009298-09-2 AZD₈₀₅₅ 
• 938443-23-3 7-chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine 
• 938443-29-9 7-(3-chloromethyl-4-methoxy-phenyl)-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine 
• 1424432-35-8 C₂₆H₃₄N₆O₃ 
• 1424432-36-9 C₂₅H₃₂N₆O₂ 
• 1424432-37-0 C₂₆H₃₄N₆O₂ 
• 1009303-44-9 (3S)-4-[7-chloro-2-[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d] pyrimidin-4-yl] 3-methyl-morpholine 
• 1424432-38-1 C₂₅H₃₁N₅O₃S 

Relevant articles and documents

Pyridopyrimidine KRAS G12C mutant protein inhibitor

The invention belongs to the technical field of medicines, and particularly relates to a pyridopyrimidine KRAS G12C mutant protein inhibitor shown in a general formula (I), pharmaceutically acceptable salts, stereoisomers and deuterated substances thereof. The invention also relates to a preparation method of the compounds, and a preparation method of the pharmaceutically acceptable salts, pharmaceutical preparations and pharmaceutical compositions containing the compounds. The invention also relates to the application of the compounds, pharmaceutically acceptable salts containing the compounds, pharmaceutical preparations and pharmaceutical compositions of the compounds in treatment of cancer proliferative diseases caused by KRAS G12C mutant protein.

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

Discovery of 1-methyl-1 H-imidazole derivatives as potent Jak2 inhibitors

Structure based design, synthesis, and biological evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described. Using the C-ring fragment from our first clinical candidate AZD1480 (24), optimization of the series led to the discovery of compound 19a, a potent, orally bioavailable Jak2 inhibitor. Compound 19a displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells. Compound 19a demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.